Alto Neuroscience (ANRO) Research & Development (2023 - 2026)

Alto Neuroscience has reported Research & Development for 4 years, with the latest figure at $20.3 million in Q1 2026.

• Quarterly Research & Development rose 103.47% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.9 million (up 18.97% YoY) and the FY2025 annual result came in at $45.6 million, down 2.93% from the prior year.
• Research & Development grew to $20.3 million in Q1 2026 per ANRO's latest filing, from $12.0 million in the prior quarter.
• Over five years, Research & Development peaked at $20.3 million in Q1 2026 and troughed at -$20.4 million in Q4 2023.
• A 4-year average of $8.7 million and a median of $10.5 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development jumped 152.82% in 2024, then dropped 19.41% in 2025.
• Over 4 years, Research & Development stood at -$20.4 million in 2023, then surged by 152.82% to $10.8 million in 2024, then increased by 11.07% to $12.0 million in 2025, then surged by 69.17% to $20.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $20.3 million, $12.0 million, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.